The use of bevacizumab, an anti-VEGF monoclonal antibody11, combined with chemotherapy in mCRC patients showed promising results such as reduction of tumor size, increased overall survival / progression-free survival in patients with liver metastases and reduction of circulating EGFL7, associated with VEGFA reduction11–13. Here, EGFL7 is linked to neoplasm.